2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.14 (Poster) Healthcare Utilization Amongst Patients with NSCLC Stratified by Metastatic Status Before and After Testing with a Host Immune Classifier (HIC)

PP01.14 (Poster) Healthcare Utilization Amongst Patients with NSCLC Stratified by Metastatic Status Before and After Testing with a Host Immune Classifier (HIC)

Back to course

Pdf Summary

A study presented at the IASLC 2023 North America Conference on Lung Cancer examined healthcare utilization among patients with non-small cell lung cancer (NSCLC) based on their metastatic status before and after testing with a Host Immune Classifier (HIC). The HIC is a blood-based immune profiling test that provides information about a patient's immune response to their lung cancer.<br /><br />The study found that patients with metastatic NSCLC had higher healthcare costs compared to patients with stable disease. The HIC test categorized patients as either HIC-Hot (HIC-H) or HIC-Cold (HIC-C), with HIC-H patients generally responding well to standard therapies and HIC-C patients less likely to respond. The objective of the study was to describe healthcare resource utilization and costs among patients with lung cancer before and after using the HIC test.<br /><br />The study analyzed data from patients enrolled in the MarketScan-Biodesix linked file who had a HIC test between January 2016 and June 2021. The analysis focused on patients with metastatic or non-metastatic disease. The study found that among metastatic patients, those with HIC-H had fewer inpatient admissions and primary care visits compared to HIC-C patients. However, HIC-H patients had more emergency visits and filled more prescriptions compared to HIC-C patients.<br /><br />In terms of lung cancer related treatment utilization, HIC-H patients filled fewer opioids and asthma medications compared to HIC-C patients. In the post-index period, HIC-H patients had lower utilization of antiemetics/appetite stimulants but higher utilization of antidepressants compared to HIC-C patients.<br /><br />The study also found differences in imaging and interventions. HIC-H patients in the non-metastatic cohort had higher rates of imaging scans, particularly CT scans. They were also more likely to undergo lobectomy but less likely to undergo lung removal compared to HIC-C patients.<br /><br />The study concluded that there are significant differences in healthcare utilization among patients with NSCLC based on their HIC test results and metastatic status. Identifying metastatic and HIC status may help in identifying patients who would benefit from specific interventions and support. Further research will focus on costs stratified by HIC status and metastatic status.

Asset Subtitle

Kimberly Le

Keywords

IASLC 2023 North America Conference on Lung Cancer

non-small cell lung cancer

metastatic status

Host Immune Classifier

HIC

healthcare utilization

blood-based immune profiling test

lung cancer treatment

healthcare costs

patient interventions